drugset / Trial / NCT00667407

Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma

NCT00667407

Phase 3 Completed 627 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the Efficacy and Safety of Levalbuterol versus Racemic Albuterol in the Treatment of Acute Asthma.

Timeline

Start
2000-11
Primary completion
2002-08
Completion
2002-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Levalbuterol Other / unclassified 1.25 mg Inhaled
Comparator racemic albuterol Unknown 2.5 mg Inhaled

Indications